Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 100 of 232 entries
View as:

AVN944 in Combination With Gemcitabine for the Treatment of Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00493441 Org: User:
Start: 06/30/07 End: 12/31/09 Due: 12/31/10

A Phase 3 Study of Tezacaftor (VX-661) in Combination With Ivacaftor (VX-770) in Subjects Aged 12 Years and Older With Cystic Fibrosis (CF), Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Responsive to Ivacaftor

Phase: N/A Priority: Normal
NCT ID: NCT02412111 Org: User:
Start: 06/30/15 End: 09/30/17 Due: 09/30/18

A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Subjects With Genotype 1 Chronic Hepatitis C Chronic Hepatitis C

Phase: N/A Priority: Normal
NCT ID: NCT01842451 Org: User:
Start: 06/30/13 End: 05/31/14 Due: 05/31/15

A Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics, of VX-993

Phase: N/A Priority: Normal
NCT ID: NCT06226454 Org: User:
Start: 01/04/24 End: 06/12/24 Due: 06/12/25

A Study Evaluating Efficacy and Safety of VX-993 for Acute Pain After a Bunionectomy

Phase: N/A Priority: Normal
NCT ID: NCT06619847 Org: User:
Start: 10/29/24 End: 05/27/25 Due: 05/27/26

Long-term Safety of Lumacaftor/Ivacaftor in Participants With Cystic Fibrosis Who Are Homozygous for F508del and 12 to <24 Months of Age at Treatment Initiation

Phase: N/A Priority: Normal
NCT ID: NCT04235140 Org: User:
Start: 02/24/20 End: 08/22/23 Due: 08/22/24

Natural History Study of Exocrine Pancreatic Function in Infants With Cystic Fibrosis (CF)

Phase: N/A Priority: Normal
NCT ID: NCT06506773 Org: User:
Start: 07/09/24 End: 08/31/26 Due: 08/31/27

Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older

Phase: N/A Priority: Normal
NCT ID: NCT06460506 Org: User:
Start: 11/21/24 End: 09/30/27 Due: 09/30/28

A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis

Phase: N/A Priority: Normal
NCT ID: NCT03912233 Org: User:
Start: 04/30/19 End: 12/10/19 Due: 12/10/20

Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of Age

Phase: N/A Priority: Normal
NCT ID: NCT05882357 Org: User:
Start: 06/27/23 End: 10/06/25 Due: 10/06/26

A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection

Phase: N/A Priority: Normal
NCT ID: NCT01080222 Org: User:
Start: 08/31/10 End: 11/30/13 Due: 11/30/14

Evaluation of the Efficacy and Safety of VX-814 in Subjects With the PiZZ Genotype

Phase: N/A Priority: Normal
NCT ID: NCT04167345 Org: User:
Start: 01/13/20 End: 11/14/20 Due: 11/14/21

A Safety Study for Cethrin (BA-210) in the Treatment of Acute Thoracic and Cervical Spinal Cord Injuries

Phase: N/A Priority: Normal
NCT ID: NCT00500812 Org: User:
Start: 02/28/05 End: 02/28/09 Due: 02/28/10

A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation

Phase: N/A Priority: Normal
NCT ID: NCT01807949 Org: User:
Start: 04/30/13 End: 04/30/14 Due: 04/30/15

Roll-Over Study of Ivacaftor in Cystic Fibrosis Pediatric Subjects With a CF Transmembrane Conductance Regulator Gene (CFTR) Gating Mutation

Phase: N/A Priority: Normal
NCT ID: NCT01946412 Org: User:
Start: 12/31/13 End: 12/31/15 Due: 12/31/16

A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes

Phase: N/A Priority: Normal
NCT ID: NCT05791201 Org: User:
Start: 05/16/23 End: 05/29/26 Due: 05/29/27

A Phase 3 Study of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)

Phase: N/A Priority: Normal
NCT ID: NCT03525444 Org: User:
Start: 06/15/18 End: 04/24/19 Due: 04/24/20

A Study to Evaluate Pharmacokinetics (PK) and Safety of Inaxaplin in Participants With Renal Impairment

Phase: N/A Priority: Normal
NCT ID: NCT05865171 Org: User:
Start: 06/12/23 End: 06/12/24 Due: 06/12/25

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age and Have an Ivacaftor-Responsive CFTR Mutation

Phase: N/A Priority: Normal
NCT ID: NCT02725567 Org: User:
Start: 06/02/16 End: 06/28/22 Due: 06/28/23

A Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis (CF) Particpants 6 Years and Older and F/MF Genotypes

Phase: N/A Priority: Normal
NCT ID: NCT04545515 Org: User:
Start: 01/11/21 End: 03/24/23 Due: 03/24/24

A Study Evaluating the Relative Bioavailability and Food Effect of a Tablet Formulation of VX-147

Phase: N/A Priority: Normal
NCT ID: NCT05955872 Org: User:
Start: 07/19/23 End: 09/02/23 Due: 09/02/24

A Study to Evaluate the Efficacy and Safety of VX-765 in Subjects With Treatment-Resistant Partial Epilepsy

Phase: N/A Priority: Normal
NCT ID: NCT01501383 Org: User:
Start: 12/31/11 End: - Due: -

Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age

Phase: N/A Priority: Normal
NCT ID: NCT05422222 Org: User:
Start: 06/21/22 End: 06/30/30 Due: 06/30/31

Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older

Phase: N/A Priority: Normal
NCT ID: NCT05844449 Org: User:
Start: 08/11/23 End: 07/30/29 Due: 07/30/30

Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)

Phase: N/A Priority: Normal
NCT ID: NCT06696443 Org: User:
Start: 12/18/24 End: 01/25/27 Due: 01/25/28